employ
solid
phase
immunoassay
techniqu
measur
immunoglobulin
g
igg
class
antibodi
ebv
virion
defin
protein
individu
schizophrenia
individu
without
histori
psychiatr
disord
western
blot
test
perform
document
reactiv
specif
ebv
protein
polygen
risk
schizophrenia
calcul
genom
sequenc
array
level
antibodi
group
compar
multivari
analys
incorpor
clinic
genet
demograph
measur
result
individu
schizophrenia
mark
elev
level
antibodi
ebv
virion
compar
control
popul
analys
indic
increas
level
reactiv
ebvvir
capsid
antibodi
vca
ebv
nuclear
human
herpesvirus
western
blot
analysi
confirm
increas
reactiv
vca
protein
group
individu
schizophrenia
document
lack
increas
level
antibodi
genet
analys
indic
addit
effect
increas
level
antibodi
ebv
virion
genet
suscept
schizophrenia
individu
elev
level
type
marker
greater
odd
schizophrenia
diagnosi
conclus
individu
schizophrenia
increas
level
antibodi
ebv
protein
indic
aberr
respons
ebv
infect
aberr
respons
may
contribut
immunopatholog
schizophrenia
relat
disord
schizophrenia
seriou
neuropsychiatr
disord
uncertain
etiolog
lifetim
preval
approxim
unit
state
schizophrenia
clear
genet
underpin
current
known
gene
explain
portion
diseas
risk
addit
genet
factor
environment
exposur
identifi
increas
risk
diseas
environment
factor
associ
increas
risk
schizophrenia
includ
winterspr
birth
urban
birth
matern
preeclampsia
perinat
postnat
infect
potenti
role
infect
etiopathogenesi
schizophrenia
support
associ
schizophrenia
risk
gene
encod
hla
factor
control
immun
respons
infecti
agent
epsteinbarr
viru
ebv
also
known
human
herpesviru
member
herpesvirida
famili
ebv
lymphotrop
viru
produc
latent
infect
immunomodulatori
effect
primari
infect
ebv
often
associ
selflimit
fever
adenopathi
follow
acut
infect
viru
persist
host
b
lymphocyt
monocyt
epitheli
cell
asymptomat
salivari
viral
shed
lead
onward
transmiss
ebv
establish
latenc
mani
bodi
site
includ
brain
reactiv
associ
enceph
brainspecif
immun
respons
immun
respons
ebv
infect
monitor
measur
level
antibodi
direct
antigen
deriv
virion
well
specif
ebv
protein
commonli
measur
antiebv
antibodi
includ
antiearli
antigen
ea
aris
earli
cours
infect
decreas
month
viral
capsid
antibodi
vca
also
aris
earli
infect
persist
extend
period
time
antieb
nuclear
antigen
ebv
na
ebna
aris
late
infect
persist
extend
period
time
supplementari
figur
respons
addit
ebv
protein
measur
western
blot
techniqu
defin
immun
respons
infect
ebv
infect
associ
number
autoimmun
disord
includ
multipl
sclerosi
system
lupu
autoimmun
enceph
fibromyalgia
mani
case
immun
respons
ebv
individu
disord
aberr
differ
immun
respons
note
otherwis
healthi
individu
term
respons
ea
vca
ebna
antigen
mani
individu
ebvassoci
disord
psychiatr
symptom
cours
ill
exampl
disord
system
lupu
cognit
dysfunct
report
occur
patient
psychosi
individu
multipl
sclerosi
also
rel
high
rate
cognit
impair
psychiatr
symptom
includ
psychosi
howev
studi
ebv
exposur
individu
schizophrenia
thu
measur
level
antibodi
ebv
virion
defin
ebv
protein
cohort
individu
schizophrenia
compar
level
group
control
individu
without
histori
psychiatr
symptom
studi
popul
consist
individu
schizophrenia
diagnosi
without
histori
psychiatr
disord
detail
recruit
evalu
individu
popul
previous
describ
individu
schizophrenia
met
follow
criteria
age
inclus
diagnosi
schizophrenia
schizoaffect
disord
meet
criteria
diagnost
statist
manual
mental
disord
fourth
edit
dsmiv
current
receiv
antipsychot
medic
individu
nonpsychiatr
control
sampl
met
criteria
age
inclus
absenc
current
past
psychiatr
disord
confirm
screen
structur
clinic
interview
dsmiv
axi
disord
nonpati
edit
scidinp
particip
assess
deficit
syndrom
put
schizophrenia
subtyp
compris
individu
schizophrenia
primari
endur
neg
symptom
restrict
affect
diminish
social
drive
addit
detail
method
recruit
evalu
present
supplementari
materi
method
studi
approv
institut
review
board
sheppard
pratt
health
system
john
hopkin
medic
institut
follow
establish
guidelin
particip
provid
written
inform
consent
studi
procedur
explain
immunoglobulin
g
igg
antibodi
ebv
antigen
deriv
intact
virion
measur
mean
solid
phase
enzym
immunoassay
detail
procedur
provid
supplementari
materi
method
igg
antibodi
ebvvca
ebv
nuclear
measur
solid
phase
immunoassay
employ
commerci
avail
assay
kit
ibl
america
igg
antibodi
human
herpesvirus
measur
similar
procedur
complet
baselin
sampl
set
consist
n
individu
blood
sampl
avail
immunoassay
test
quantit
western
blot
assay
perform
use
method
present
supplementari
materi
depict
supplementari
figur
sampl
avail
western
blot
individu
individu
schizophrenia
control
individu
sampl
avail
western
blot
differ
significantli
overal
studi
popul
demograph
clinic
variabl
dna
extract
whole
blood
analyz
genet
polymorph
use
illumina
array
polygen
risk
score
calcul
use
pvalu
cutoff
p
inclus
individu
polymorph
use
calcul
polygen
risk
score
detail
method
use
provid
supplementari
materi
result
assay
compar
individu
schizophrenia
control
employ
parametr
nonparametr
regress
model
detail
statist
method
present
supplementari
materi
light
perform
set
immunoassay
measur
ebv
virion
ebv
vca
critic
valu
p
employ
indic
statist
signific
assay
use
measur
valu
p
consid
repres
trend
demograph
clinic
characterist
individu
studi
individu
schizophrenia
nonpsychiatr
control
present
tabl
within
schizophrenia
group
particip
follow
diagnos
per
dsmiv
criteria
schizophreniform
disord
n
paranoid
subtyp
n
undifferenti
subtyp
n
schizophrenia
subtyp
n
schizoaffect
disord
n
total
schizophrenia
particip
met
criteria
deficit
syndrom
follow
antipsychot
medic
commonli
receiv
time
studi
assess
person
schizophrenia
group
risperidon
n
olanzapin
n
clozapin
n
ziprasidon
n
schizophrenia
particip
also
receiv
addit
type
psychotrop
medic
includ
antidepress
n
valproat
n
initi
analys
perform
compar
quantit
level
antibodi
diagnost
group
shown
figur
significantli
elev
level
igg
antibodi
ebv
virion
schizophrenia
group
vs
control
group
effect
size
ci
p
associ
confirm
analysi
employ
nonparametr
interquartil
regress
analysi
effect
size
ci
p
also
trend
toward
increas
level
igg
antibodi
vca
schizophrenia
group
effect
size
ci
p
howev
level
antibodi
differ
significantli
group
histogram
distribut
valu
ebv
antibodi
individu
schizophrenia
control
shown
supplementari
figur
preval
antibodi
case
control
popul
display
supplementari
tabl
also
measur
antibodi
human
herpesvirus
cmv
vzv
signific
differ
schizophrenia
control
group
antibodi
level
trend
toward
decreas
level
antibodi
cmv
individu
schizophrenia
effect
size
ci
p
also
examin
odd
ratio
associ
elev
level
antibodi
defin
valu
greater
predefin
percentil
level
control
group
adjust
age
sex
race
cigarett
smoke
matern
educ
depict
figur
found
increas
odd
elev
antibodi
ebv
virion
schizophrenia
group
rel
cutoff
greater
ci
p
ci
p
ci
p
percentil
level
antibodi
control
found
trend
increas
odd
antibodi
vca
schizophrenia
group
vs
control
group
cutoff
greater
ci
p
ci
p
percentil
well
signific
effect
ci
p
percentil
level
antibodi
control
signific
differ
odd
associ
increas
level
antibodi
measur
reactiv
sampl
toward
ebv
protein
employ
quantit
western
blot
assay
system
shown
figur
signific
increas
relat
schizophrenia
diagnosi
level
antibodi
vca
effect
size
ci
p
vca
effect
size
ci
p
vca
effect
size
ci
p
viral
protein
effect
size
ci
p
also
trend
toward
increas
level
schizophrenia
group
associ
antibodi
vca
effect
size
ci
p
well
earli
antigen
ead
effect
size
ci
p
schizophreniaassoci
increas
antibodi
antigen
includ
earli
antigen
examin
bivari
relationship
antibodi
ebv
virion
clinic
demograph
variabl
within
group
individu
schizophrenia
term
basic
demograph
variabl
level
antibodi
ebv
virion
posit
associ
increas
age
correl
coeffici
ci
p
femal
sex
f
p
lower
level
matern
educ
correl
coeffici
ci
p
cigarett
smoke
f
p
noncaucasian
race
f
p
particip
educ
level
age
onset
ill
durat
birth
outsid
unit
state
canada
p
employ
regress
model
examin
relationship
level
antibodi
ebv
virion
clinic
variabl
describ
supplementari
method
employ
age
sex
race
cigarett
smoke
matern
educ
found
level
antibodi
ebv
virion
significantli
associ
presenc
deficit
syndrom
effect
size
ci
p
administr
medic
valproat
effect
size
ci
p
signific
associ
panss
symptom
score
rban
cognit
score
bmi
medic
p
also
examin
interact
ebv
antibodi
genet
risk
schizophrenia
measur
polygen
risk
score
employ
regress
model
adjust
age
sex
race
cigarett
smoke
matern
educ
polygen
risk
score
associ
increas
risk
schizophrenia
studi
popul
effect
size
ci
p
significantli
associ
level
antiebv
virion
antiebv
vca
antibodi
p
analyz
term
percentil
polygen
risk
score
percentil
associ
schizophrenia
diagnosi
odd
ratio
ci
p
polygen
risk
score
percentil
associ
schizophrenia
diagnosi
odd
ratio
ci
p
appar
addit
effect
odd
ratio
associ
polygen
risk
score
ebv
virion
antibodi
odd
ratio
schizophrenia
diagnosi
associ
ebv
virion
antibodi
level
schizophrenia
polygen
risk
score
percentil
ci
p
adjust
age
sex
race
matern
educ
cigarett
smoke
genotyp
array
odd
ratio
schizophrenia
diagnosi
associ
ebv
virion
antibodi
level
schizophrenia
polygen
risk
score
greater
percentil
ci
p
signific
statist
interact
level
ebv
virion
antibodi
polygen
risk
score
relat
associ
schizophrenia
p
followup
sampl
obtain
analyz
individu
individu
schizophrenia
control
median
interv
initi
followup
day
interquartil
rang
individu
level
ebv
antibodi
virion
vca
first
last
sampl
period
highli
correl
effect
size
respect
none
differ
level
measur
first
second
sampl
statist
signific
p
adjust
age
sex
race
diagnosi
matern
educ
time
interv
first
second
sampl
found
individu
schizophrenia
increas
level
igg
antibodi
ebv
virion
compar
control
group
differ
independ
demograph
variabl
known
affect
ebv
exposur
age
sex
race
socioeconom
statu
measur
matern
educ
also
measur
antibodi
specif
viral
protein
studi
indic
individu
schizophrenia
aberr
immun
respons
ebv
elev
level
antibodi
ebv
vca
like
particip
studi
undergon
primari
ebv
infect
time
past
evidenc
presenc
low
level
antibodi
ebv
earli
antigen
ea
gener
individu
past
infect
ebv
increas
level
igg
class
antibodi
vca
antigen
level
ebv
antibodi
studi
popul
rel
stabl
extend
period
time
sinc
level
chang
significantli
individu
followup
sampl
avail
find
suggest
aberr
immun
respons
unlik
relat
time
sampl
rel
stabl
within
individu
time
addit
longitudin
studi
done
assess
stabil
marker
time
antibodi
herpesvirus
includ
cmv
vzv
significantli
increas
popul
individu
schizophrenia
find
indic
increas
level
antibodi
ebv
virion
found
individu
reflect
heighten
immun
respons
human
herpesviru
specif
ebv
within
group
infecti
agent
note
healthi
individu
gener
develop
maintain
approxim
equal
level
antibodi
ebv
vca
ebna
protein
follow
resolut
acut
infect
find
increas
level
vca
antibodi
individu
schizophrenia
thu
reflect
aberr
immun
respons
ebv
infect
aberr
respons
ebv
describ
rang
ebvassoci
disord
includ
autoimmun
diseas
multipl
sclerosi
system
lupu
well
neoplast
condit
nasopharyng
carcinoma
increas
level
antibodi
ebv
virion
vca
protein
associ
cognit
function
symptom
score
associ
increas
preval
deficit
syndrom
ebv
virion
antibodi
also
significantli
increas
individu
receiv
moodstabil
medic
valproat
find
verifi
larger
sampl
interest
light
immunomodulatori
effect
medic
like
relat
effect
histon
deacetyl
valproat
also
use
treatment
ebvassoci
tumor
base
abil
modul
ebv
gene
express
increas
level
ebv
antibodi
also
margin
associ
increas
preval
cigarett
smoke
pattern
reactiv
ebv
protein
studi
cohort
analyz
perform
western
blot
analys
direct
igg
antibodi
direct
ebv
protein
analys
confirm
signific
reactiv
vca
protein
ebv
protein
well
lack
reactiv
interest
signific
increas
reactiv
individu
schizophrenia
compar
control
materi
provid
manufactur
quantit
immunoblot
system
employ
state
viral
strain
use
produc
blot
strip
although
yet
confirm
ident
protein
present
blot
strip
like
repres
truncat
form
ebna
leader
protein
garib
et
al
report
produc
ebv
strain
predomin
wildtyp
strain
suggest
individu
schizophrenia
might
differenti
expos
ebv
variant
mutat
similar
strain
primari
ebv
infect
gener
occur
adolesc
follow
viral
transmiss
facilit
oral
contact
infect
adolesc
often
manifest
syndrom
fever
pharyng
lymphadenopathi
splenomegali
gener
refer
infecti
mononucleosi
case
infecti
mononucleosi
selflimit
follow
increas
antibodi
vca
ebna
protein
time
primari
ebv
infect
interest
term
first
manifest
schizophrenia
also
often
occur
adolesc
note
regard
khandak
et
al
found
previou
exposur
ebv
measur
vca
antibodi
associ
subsequ
psychot
experi
adolesc
studi
indic
sourc
ebv
antigen
test
immunoassay
import
evalu
associ
ebv
exposur
schizophrenia
diagnosi
thu
interest
dewitt
et
al
find
associ
level
antibodi
ebv
schizophrenia
diagnosi
howev
measur
ebna
antibodi
dewitt
l
person
commun
marker
ebv
exposur
find
consist
consist
result
studi
measur
ebv
antibodi
individu
schizophrenia
difficult
evalu
without
addit
inform
relat
immun
respons
defin
ebv
protein
reason
alter
level
antibodi
ebv
protein
specif
ebv
protein
known
certainti
possibl
mechan
associ
includ
one
relat
viru
host
respons
term
viru
differenti
respons
infect
might
relat
variat
time
primari
ebv
exposur
genom
composit
pathogen
infect
ebv
possibl
reexposur
differ
strain
ebv
virolog
analysi
sampl
obtain
individu
prospect
studi
requir
address
possibl
alter
immun
respons
ebv
infect
could
also
base
host
factor
genet
environment
factor
term
genet
factor
found
addit
effect
increas
ebv
antibodi
increas
genet
risk
combin
odd
ratio
individu
valu
percentil
measur
howev
statist
signific
associ
interact
level
ebv
virion
antibodi
polygen
risk
score
suggest
risk
associ
genet
suscept
increas
level
ebv
virion
antibodi
independ
howev
larger
sampl
size
might
employ
detect
low
level
interact
furthermor
addit
genet
studi
requir
defin
genet
contribut
aberr
respons
ebv
infect
found
individu
schizophrenia
possibl
use
combin
immun
genet
marker
diagnosi
manag
schizophrenia
import
area
futur
studi
antigenspecif
antibodi
addit
herpesvirus
virus
might
also
examin
goal
incorpor
approach
term
environment
factor
note
found
associ
level
antibodi
ebv
virion
protein
cigarett
smoke
individu
schizophrenia
interact
ebv
exposur
cigarett
smoke
also
note
ebvassoci
disord
multipl
sclerosi
possibl
base
mani
immunomodulatori
effect
cigarett
smoke
factor
time
interact
cigarett
smoke
ebv
exposur
term
risk
schizophrenia
address
prospect
studi
possibl
effect
lymphotrop
virus
ebv
environment
factor
affect
bcell
activ
immunopatholog
schizophrenia
subject
futur
investig
neurobiolog
mechan
increas
level
ebv
virion
antibodi
might
associ
schizophrenia
entir
known
one
potenti
scenario
individu
aberr
ebv
immun
respons
underw
previou
replic
ebv
within
central
nervou
system
possibl
consist
report
psychosi
individu
undergo
ebv
enceph
find
increas
level
ebv
vca
antibodi
csf
individu
psychiatr
disord
also
possibl
psychiatr
symptom
relat
neuroinflammatori
effect
brain
includ
alter
neurotransmitt
receptor
interact
found
rang
autoimmun
disord
affect
brain
conclus
studi
indic
mani
individu
schizophrenia
aberr
immun
respons
ebv
number
therapeut
intervent
avail
modul
ebv
infect
includ
antivir
medic
pharmacolog
compound
modul
immun
respons
increas
understand
role
ebv
infect
might
thu
lead
novel
method
prevent
treatment
schizophrenia
supplementari
materi
avail
schizophrenia
bulletin
onlin
